What are the approved and off‑label indications for clonidine?

Clonidine: Approved and Off-Label Indications

Clonidine is FDA-approved for hypertension, with extended-release formulations approved for ADHD in children, and has established off-label uses including menopausal hot flashes, neonatal opioid withdrawal syndrome, and various psychiatric conditions. 1, 2

FDA-Approved Indications

Hypertension

• Clonidine hydrochloride tablets are indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents 1
• As a centrally acting alpha-2 adrenergic agonist, it reduces peripheral vascular resistance and lowers blood pressure 2
• Available in oral tablets (0.1 mg, 0.2 mg) and transdermal patches (0.1 mg, 0.2 mg, 0.3 mg) 2

ADHD (Extended-Release Formulations Only)

• Extended-release clonidine is FDA-approved for ADHD in children as monotherapy or adjunctive therapy with stimulants 2
• The mechanism involves postsynaptic alpha-2 agonism in the prefrontal cortex, enhancing noradrenergic neurotransmission and strengthening top-down guidance of attention, thought, and working memory 2
• Approved in multiple Asian countries including India, Republic of Korea, and Japan for pediatric ADHD 2
• Extended-release guanfacine and extended-release clonidine are the only non-stimulants with sufficient evidence for adjunctive therapy with stimulants to achieve FDA approval 2
• Starting dose is 0.1 mg at bedtime, titrated to twice-daily administration with maximum dose of 0.4 mg/day 2

Established Off-Label Uses

Menopausal Hot Flashes

• Clonidine demonstrates mild to moderate efficacy in treating menopausal hot flashes, reducing frequency by up to 46% 2
• Particularly useful in breast cancer patients on tamoxifen who cannot use hormonal therapy 2
• Dosing: 0.1 mg/day oral or transdermal clonidine 2
• Clonidine may be useful for mild to moderate hot flashes and is suitable for those wishing to avoid SSRIs/SNRIs or gabapentin 2
• Common side effects include dry mouth and insomnia or drowsiness, with 40% discontinuation rate in clinical trials 2
• Doses used for hot flashes do not appear to affect blood pressure 2

Neonatal Opioid Withdrawal Syndrome (NOWS)

• Clonidine is used as a secondary pharmacologic agent for NOWS when primary opioid therapy (morphine, methadone, or buprenorphine) is insufficient 2
• Dosing: 1 mcg/kg PO every 4 hours, with weaning by increasing intervals from q4h to q8h to q12h to discontinuation 2
• Phenobarbital is associated with shorter length of hospitalization compared with clonidine, but clonidine has no known risk for neurodevelopmental delays 2
• Blood pressure and heart rate monitoring required during clonidine treatment 2

Chronic Hypertension in Pregnancy

• Clonidine has been used mainly in the third trimester without reports of adverse outcomes 2
• Usual dose: 0.1-0.3 mg per day in divided doses, up to 1.2 mg per day 2
• Methyldopa remains first-line due to best long-term safety record, but clonidine is an acceptable alternative 2

Other Psychiatric and Medical Uses

• Opiate detoxification, post-traumatic stress disorder, and Tourette syndrome 3
• Neuroleptic-induced akathisia, stimulant-induced insomnia, and clozapine-induced sialorrhea 3
• Pediatric sleep problems, particularly in patients with neurological and neurodevelopmental disorders, though evidence is limited 4
• Perioperative medicine for anxiolysis, sedation, opioid-sparing effects, and reducing stress response to surgery 5

Important Safety Considerations

Cardiovascular Effects

• Common adverse effects include somnolence, fatigue, irritability, insomnia, nightmares, dry mouth, sedation, bradycardia, and hypotension 2
• Monitor heart rate in patients receiving clonidine with agents affecting sinus node function or AV nodal conduction (digitalis, calcium channel blockers, beta-blockers) 1
• Sinus bradycardia requiring hospitalization and pacemaker insertion reported with concomitant diltiazem or verapamil use 1

Withdrawal Risk

• Rebound hypertension after abrupt discontinuation is a critical concern—clonidine must be tapered rather than suddenly stopped 2
• Continue clonidine to within 4 hours of surgery and resume as soon as possible thereafter 1

Drug Interactions

• Tricyclic antidepressants may reduce clonidine's hypotensive effect, necessitating dose increase 1
• Clonidine potentiates CNS-depressive effects of alcohol, barbiturates, and other sedating drugs 1
• Neuroleptics may induce or exacerbate orthostatic regulation disturbances when combined with clonidine 1

Special Populations

• Pregnancy Category C: crosses placental barrier; use only if clearly needed 1
• Excreted in human milk; exercise caution when administering to nursing women 1
• Safety and effectiveness in pediatric patients not established in adequate controlled trials for most indications except extended-release formulation for ADHD 1